Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Research & Development: NT$72.02 Mil (TTM As of Dec. 2025)


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
49 GF Score
Price NT$39.65
GF Value NT$25.61
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Research & Development?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 -1.25% 49 Research & Development is NT$72.02 Mil as of Dec. 2025. GuruFocus rates ROCO:7427 with a GF Score™ of 49/100 and a GF Value™ of NT$25.61 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Great Novel Therapeutics Biotech & Medicals's Research & Development for the six months ended in Dec. 2025 was NT$39.32 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$72.02 Mil.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Great Novel Therapeutics Biotech & Medicals Research & Development Related Terms

Great Novel Therapeutics Biotech & Medicals Research & Development Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Research & Development Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 19.11 38.53 53.13 85.09 72.02

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.50 48.70 36.39 32.69 39.32
ROCO:7427
49GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$72.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$72.02 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Research & Development of NT$72.02 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Research & Development too high?
Great Novel Therapeutics Biotech & Medicals' current Research & Development is NT$72.02 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Research & Development compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Research & Development of NT$72.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Research & Development is NT$72.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.61, compared to a current price of NT$39.65 — trading 54.8% above its estimated fair value. The current Research & Development is NT$72.02 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Research & Development is NT$72.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$39.65 is trading 54.8% above its estimated GF Value™ of NT$25.61. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Research & Development: NT$72.02 Mil
  • GF Value™: NT$25.61 vs. price of NT$39.65 (54.8% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
49GF Score

Get the complete analysis for ROCO:7427

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.65
Price
NT$25.61
GF Value